OBJECTIVE: To perform a systematic review of literature on the safety and efficacy of vaccinations in patients who are receiving dupilumab and to provide expert guidance on the use of vaccines in patients who are receiving dupilumab.
METHODS: A systematic review of the literature was performed, and an expert Delphi Panel was assembled.
RESULTS: The available literature on patients who received vaccinations while using dupilumab overall suggests that live vaccines are safe and that the vaccine efficacy, in general, is not affected by dupilumab. The expert Delphi panel agreed that the use of vaccines in patients receiving dupilumab was likely safe and effective.
CONCLUSIONS: Vaccines (including live vaccines) can be administered to patients receiving dupilumab in a shared decision-making capacity.
目的:对接受dupilumab的患者接种疫苗的安全性和有效性的文献进行系统回顾,并为接受dupilumab的患者使用疫苗提供专家指导。
方法:对文献进行了系统回顾,并进行了专家Delphi小组。
结果:关于接受疫苗接种而使用dupilumab的患者的现有文献表明,活疫苗是安全的,疫苗的有效性,总的来说,不受dupilumab的影响。专家Delphi小组同意在dupilumab患者中使用疫苗可能是安全有效的。
结论:疫苗(包括活疫苗)可以以共同的决策能力在dupilumab上给予患者。